Register for our free email digests:
Latest From Intas Pharmaceuticals Ltd.
Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.
Patients For Affordable Drugs Founder David Mitchell alleges Celgene's unlawful delay tactics like REMS obstruction kept generic versions of Thalomid and Revlimid off the market, forcing plaintiffs to pay higher costs.
Intas Pharmaceuticals has claimed that certain adverse events reported with its Lucentis biosimilar were not caused by “qualitative aspects” of the product and that physicians have since “very satisfactorily” used subsequent batches of the vascular endothelial growth factor inhibitor in India.
Biosimilar sponsors are 0-3 so far in attempts to win US FDA approval for copies of Amgen’s pegfilgrastim (Neulasta). FDA’s recent review of a novel clotting factor formulation offers a clue why it is turning out to be harder than it seems to copy a pegylated protein.
- Consumables, Central Supplies
- Therapeutic Areas
- Engineering & Research Associates Inc.
- North America
- Parent & Subsidiaries
- Senior Management
Roger Vogel, Pres. & CEO
Alan Smith, CFO
Bill Thomasson, COO
- Contact Info
Phone: (520) 881-6555
100 N. Tucson Blvd.
Tucson, AZ 85716
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.